Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Heron Therapeutics	Myovant Sciences	ADC Therapeutics	Harmony Biosciences	Generation Bio
Symbol	NASDAQ:HRTX	NYSE:MYOV	NYSE:ADCT	NASDAQ:HRMY	NASDAQ:GBIO
Price Information
Current Price	$14.21	$22.17	$21.64	$31.70	$31.50
52 Week Range	Buy	Hold	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.3	1.7	1.4	1.8
Analysis Score	3.4	3.2	3.4	3.5	3.5
Community Score	2.7	2.6	3.8	2.1	3.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.8	0.8	0.8
Earnings & Valuation Score	0.6	0.6	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Buy	Buy
Consensus Price Target	$27.50	$31.57	$48.75	$51.67	$40.60
% Upside from Price Target	93.53% upside	42.41% upside	125.28% upside	62.99% upside	28.89% upside
Trade Information
Market Cap	$1.38 billion	$2.00 billion	$1.48 billion	$1.70 billion	$1.75 billion
Beta	1.52	2.99	N/A	N/A	N/A
Average Volume	1,258,420	888,292	327,142	136,360	603,823
Sales & Book Value
Annual Revenue	$145.97 million	N/A	$2.34 million	N/A	N/A
Price / Sales	9.91	N/A	637.10	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$4.48 per share	($1.21) per share	N/A	N/A	N/A
Price / Book	3.17	N/A	∞	N/A	N/A
Profitability
Net Income	$-204,750,000.00	$-288,990,000.00	$-116,480,000.00	N/A	N/A
EPS	($2.50)	($3.37)	($2.36)	N/A	N/A
Trailing P/E Ratio	N/A	N/A	N/A	0.00	0.00
Forward P/E Ratio	N/A	N/A	N/A	27.33	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-216.18%	N/A	N/A	N/A	N/A
Return on Equity (ROE)	-65.06%	N/A	N/A	N/A	N/A
Return on Assets (ROA)	-49.14%	-201.20%	N/A	N/A	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.28%	2.04%	N/A
Current Ratio	3.60%	1.75%	15.55%	7.87%	31.19%
Quick Ratio	3.16%	1.75%	15.55%	7.80%	31.19%
Ownership Information
Institutional Ownership Percentage	99.01%	33.77%	40.88%	50.17%	63.26%
Insider Ownership Percentage	12.85%	3.90%	N/A	N/A	N/A
Miscellaneous
Employees	223	214	208	150	100
Shares Outstanding	101.83 million	91.48 million	68.89 million	56.90 million	56.59 million
Next Earnings Date	8/4/2021 (Estimated)	8/10/2021 (Estimated)	8/17/2021 (Estimated)	8/10/2021 (Estimated)	8/10/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Generation Bio (NASDAQ:GBIO) Trading Down 2.8% americanbankingnews.com - May 18 at 12:00 PM
	Oxurion NV: OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer finanznachrichten.de - May 17 at 3:29 AM
	OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer apnews.com - May 17 at 3:29 AM
	Carbon Fiber in Automotive Market Research Report by Component, by Material - United States Forecast to 2025 - Cumulative Impact of COVID-19 au.finance.yahoo.com - May 14 at 10:31 PM
	Generation Bio (NASDAQ:GBIO) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS americanbankingnews.com - May 13 at 12:28 PM
	Generation Bio Co. (NASDAQ:GBIO) Insider Sells $12,420.00 in Stock americanbankingnews.com - May 12 at 5:40 PM
	Generation Bio (NASDAQ:GBIO) Shares Gap Up to $30.85 americanbankingnews.com - May 12 at 11:30 AM
	Generation Bio (NASDAQ:GBIO) Shares Gap Down to $32.36 americanbankingnews.com - May 10 at 4:38 PM
	Generation Bio Co. (NASDAQ:GBIO) Receives Average Rating of "Buy" from Brokerages americanbankingnews.com - May 4 at 8:54 AM
	Generation Bio Co (GBIO) investing.com - April 30 at 3:37 PM
	Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting finance.yahoo.com - April 27 at 7:05 PM
	Generation Bio Co. (NASDAQ:GBIO) Insider Sells $97,650.00 in Stock americanbankingnews.com - April 24 at 7:12 PM
	Do Generation Bio Co. (NASDAQ:GBIO) Provide Stability And Growth? stocksregister.com - April 24 at 2:11 PM
	Generation Bio (NASDAQ:GBIO) Trading Down 3% americanbankingnews.com - April 23 at 12:52 PM
	Check this Generation Bio Co. (NASDAQ:GBIO) Analysis Before You Invest stocksregister.com - April 17 at 1:18 PM
	Generation Bio to Present at 20th Annual Needham Virtual Healthcare Conference finance.yahoo.com - April 8 at 8:03 AM
	GBIO Makes Bullish Cross Above Critical Moving Average nasdaq.com - April 1 at 5:50 PM
	Generation Bio Co. (NASDAQ:GBIO) is up 1.16% year-to-date, analysts forecast major price rally stocksregister.com - March 27 at 5:43 PM
	Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - March 18 at 9:19 AM
	Why Earnings Season Could Be Great for Generation Bio (GBIO) finance.yahoo.com - March 1 at 12:25 PM
	Generation Bio Appoints Ron Cooper to Its Board of Directors finance.yahoo.com - February 18 at 7:38 AM
	Generation Bio Co. (NASDAQ:GBIO) Jumps 7%: What Could Be on the Way Going Forward? stocksregister.com - February 7 at 11:09 PM
	Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares finance.yahoo.com - January 14 at 4:40 PM
	Generation Bio Announces Closing of Public Offering finance.yahoo.com - January 11 at 7:12 PM
	Generation Bio Announces Pricing of Public Offering finance.yahoo.com - January 6 at 11:10 PM

Date	Company	Brokerage	Action
5/13/2021	Heron Therapeutics	Stifel Nicolaus	Reiterated Rating
12/2/2020	Heron Therapeutics	SVB Leerink	Boost Price Target
8/6/2020	Heron Therapeutics	Northland Securities	Initiated Coverage
5/26/2020	Heron Therapeutics	Guggenheim	Initiated Coverage
5/18/2020	Heron Therapeutics	FIX	Initiated Coverage
4/15/2020	Heron Therapeutics	Needham & Company LLC	Reiterated Rating
2/20/2020	Heron Therapeutics	Cantor Fitzgerald	Reiterated Rating
1/15/2020	Heron Therapeutics	Cowen	Reiterated Rating
10/3/2019	Heron Therapeutics	JMP Securities	Lower Price Target
8/13/2019	Heron Therapeutics	Evercore ISI	Reiterated Rating
5/13/2021	Myovant Sciences	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target
5/3/2021	Myovant Sciences	JPMorgan Chase & Co.	Lower Price Target
1/6/2021	Myovant Sciences	The Goldman Sachs Group	Downgrade
12/21/2020	Myovant Sciences	Robert W. Baird	Boost Price Target
5/17/2021	ADC Therapeutics	Morgan Stanley	Lower Price Target
5/14/2021	ADC Therapeutics	HC Wainwright	Lower Price Target
6/9/2020	ADC Therapeutics	Bank of America	Initiated Coverage
9/14/2020	Harmony Biosciences	Jefferies Financial Group	Initiated Coverage
9/14/2020	Harmony Biosciences	Piper Sandler	Initiated Coverage
3/1/2021	Generation Bio	William Blair	Initiated Coverage
7/7/2020	Generation Bio	Wedbush	Initiated Coverage

(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources